CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 144 enrolled
Drug / intervention
ASN008 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05870865
NCT05870865Phase 2Completed
CompareCT.gov

A Randomized, Double-Blind, Vehicle-Controlled, Phase 2 Trial to Evaluate the Anti-pruritic Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN008 in Adults With Mild to Moderate Atopic Dermatitis

Formation Bio, Inc.·interventional·Posted May 23, 2023·Updated May 16, 2025

In Brief

A Phase 2 clinical trial evaluating ASN008 and ASN008 Matching Vehicle for Dermatitis, Atopic and Pruritus. Completed, enrolled 144 participants across 27 sites.

Detailed Summary

The goal of this clinical trial is to evaluate ASN008 in people with itch caused by eczema. The main questions it aims to answer are: * What is the efficacy and safety of ASN008? * What is the impact of ASN008 on itch in patients with atopic dermatitis? Participants will be asked to apply topical ASN008, or matching vehicle (placebo containing no active drug), to their eczema lesions twice daily for 4 weeks. Researchers will compare 3 different doses of ASN008 and a matching vehicle group to see which group responds best.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDermatitis, Atopic, Pruritus
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
202420252026
First PostedMay 23, 2023
Enrollment StartMay 3, 2023
Primary CompletionNov 27, 2023
Study CompletionDec 28, 2023
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 3.1 years ago

Interventions

ASN008drug

ASN008 topical gel applied twice daily.

ASN008 Matching Vehicleother

The ASN008 matching vehicle formulation matches the formulation of each ASN008 topical gel dose, but contains no ASN008.